Loading...
01/09 22:53
Loading...
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
The earnings call presents a mixed outlook. Positive aspects include improved gross margins and reduced operating expenses, along with optimistic guidance for multi-unit orders in North America. However, the company missed EPS expectations and faces regulatory and market access challenges, which could temper investor enthusiasm. The lack of a share repurchase program and unclear timelines for private payer engagement further contribute to a neutral sentiment. The company's financial performance shows slight improvement, but not enough to strongly impact the stock price positively or negatively.
Revenue Q4 2024 $5.1 million, an increase of 5% compared to $4.8 million in Q4 2023.
Gross Profit Q4 2024 $2.7 million, representing a gross margin of approximately 53%, compared to a gross profit of $2.4 million and a gross margin of 49% for Q4 2023. The increase was primarily due to improvements in supply chain and reduction in service costs.
Operating Expenses Q4 2024 $4.9 million, a 15% decrease compared to $5.8 million in Q4 2023, primarily due to a decrease in headcount, discretionary payroll, and consultant costs.
Net Loss Q4 2024 $3.4 million or $0.14 per share, compared to a net loss of $3.2 million or $0.22 per share in Q4 2023.
Cash Used in Operations Q4 2024 $1.4 million, compared to $1.6 million for the same period in 2023.
Full Year Revenue 2024 $17.9 million, down from $18.3 million in 2023, due to a difficult 2023 comparable driven by procurement cycles and the fulfillment of a $2 million pipeline inherited from Parker Hannifin.
Full Year Gross Profit 2024 $9.5 million, representing a gross margin of approximately 53%, compared to a gross profit of $9.1 million and a gross margin of 50% for 2023. The increase was due to cost savings in supply chain and a reduction in service costs.
Full Year Operating Expenses 2024 $20 million, a 17% decrease from $24.2 million in 2023, due to lower headcount, discretionary payroll, consultant, legal, and accounting costs.
Full Year Net Loss 2024 $11.3 million or $0.56 per share, compared to a net loss of $15.2 million or $1.10 per share in 2023.
Cash Used in Operations Full Year 2024 $9.8 million, down from $12.1 million for the same period in 2023.
Cash and Restricted Cash as of December 31, 2024 $6.5 million.
New Product Launch: Ekso Indigo Personal is being positioned for growth with a focus on Medicare reimbursement.
Distribution Agreement: National Seating and Mobility named as exclusive distributor for Ekso Indigo Personal in the CRT industry.
Market Expansion: Engaging Priya Healthcare to enhance market access and reimbursement for Ekso Indigo Personal.
New Market Entry: Entering the complex rehabilitation technology (CRT) space with National Seating and Mobility.
Operational Efficiency: Improvements in supply chain and inventory management have led to strong gross margins.
Cost Reduction: Operating expenses decreased by 15% due to lower headcount and discretionary costs.
Strategic Shift: Shifted focus from awareness to a scalable go-to-market strategy for Ekso Indigo Personal.
Regulatory Strategy: Developing a strategy to navigate CMS reimbursement framework for Ekso Indigo Personal.
Earnings Expectations: Ekso Bionics Holdings, Inc. missed earnings expectations with a reported EPS of $-0.14, compared to expectations of $-0.07.
Regulatory Issues: The company is navigating the complexities of coding, coverage, and payment for Medicare claims related to the Ekso Indigo Personal device, which could impact revenue generation.
Market Access Challenges: The company is working to establish an effective market access function within the CMS reimbursement framework, which is critical for the success of their products.
Supply Chain Challenges: While improvements in supply chain and inventory management have been noted, the company has faced challenges in fulfilling a $2 million pipeline inherited from a previous acquisition.
Economic Factors: The company reported a marginal year-over-year revenue decline, attributed to a difficult 2023 comparable and changes in procurement cycles with large independent delivery networks.
Operational Efficiency: Despite improvements in gross margins, the company continues to face challenges in scaling its go-to-market strategy for the Ekso Indigo Personal, which may take time to produce results.
Go-to-Market Strategy for Ekso Indigo Personal: The company is focusing on establishing an effective market access function within the CMS reimbursement framework, which is critical for driving growth.
Engagement with Priya Healthcare: Ekso Bionics has engaged Priya Healthcare to assist with reimbursement services and market access, which is expected to enhance the commercialization of their devices.
Exclusive Distribution Agreement: National Seating and Mobility has been named the exclusive distributor for the Ekso Indigo Personal device, marking entry into the complex rehabilitation technology market.
Building Backlog of Medicare Beneficiaries: The company has built a backlog of over 25 Medicare beneficiaries as potential candidates for the Ekso Indigo Personal device.
Revenue Expectations for 2025: While the majority of revenue in 2025 will still come from enterprise health, increased contributions from personal health products are anticipated.
Gross Margin Outlook: The company expects gross margins to continue trending upward as 2025 progresses.
Claims Submission Timeline: Ekso anticipates submitting Medicare claims over the next six to nine months, although there are no guarantees regarding the timing or payment.
Share Repurchase Program: None
The earnings call highlighted several negative factors: a significant revenue decline, reduced gross profit and margins, and an increased net loss. The Q&A revealed deferred sales due to regulatory issues and uncertainty in Enterprise Health sales recovery. Despite some progress in the Indego Personal business and cost management efforts, the challenges in coding, coverage, and payment processes, alongside supply chain risks and AI integration uncertainties, contribute to a negative sentiment. The lack of clear guidance on grant reliance further exacerbates concerns, likely leading to a negative stock price reaction.
The earnings call presents a mixed picture: while there are positive developments such as improved cash position, strong gross margins, and strategic partnerships, there are also concerns about revenue decline, macroeconomic uncertainties, and reliance on enterprise health. The Q&A section did not alleviate these concerns, with management unable to provide clear guidance on certain issues. The lack of a share repurchase program further tempers positive sentiment. Given these factors, the likely stock price movement is neutral, within the -2% to 2% range over the next two weeks.
The earnings call presents a mixed outlook. Positive aspects include improved gross margins and reduced operating expenses, along with optimistic guidance for multi-unit orders in North America. However, the company missed EPS expectations and faces regulatory and market access challenges, which could temper investor enthusiasm. The lack of a share repurchase program and unclear timelines for private payer engagement further contribute to a neutral sentiment. The company's financial performance shows slight improvement, but not enough to strongly impact the stock price positively or negatively.
The earnings call presents mixed signals: improved financial metrics, optimistic guidance, and expanding market presence are positive, but offset by regulatory uncertainties, competitive pressures, and supply chain risks. The lack of a share repurchase program and unclear management responses in the Q&A session further contribute to a cautious outlook. With no new partnerships or strong catalysts, the stock is likely to remain stable, resulting in a neutral sentiment.
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
